TrkA Receptor Deep Dive
Nerve Growth Factor Receptor
Biological Context
Tropomyosin receptor kinase A (TrkA, NTRK1) is the high-affinity receptor for Nerve Growth Factor (NGF). NGF binding to the extracellular domain triggers dimerization, transphosphorylation of intracellular kinase domains, and downstream survival and differentiation signaling in sensory and sympathetic neurons.
Why it matters: The NGF/TrkA axis is a validated pain target — anti-NGF antibodies (tanezumab) reached Phase III for osteoarthritis pain before safety concerns paused development. Blocking TrkA directly, instead of sequestering NGF, is an alternative strategy that would avoid systemic depletion of NGF. On the oncology side, TrkA fusions drive a subset of solid tumors and are targeted by larotrectinib / entrectinib (small molecules against the kinase domain). A de novo binder against the extracellular domain would be a complementary modality.
The Goal: Design a binder that engages the NGF-binding face of TrkA’s d5 (membrane-proximal Ig-like) domain, competing with NGF.
Interactive Structure
The viewer below shows the extracellular d5 domain of TrkA (chain X) in complex with NGF (chains V, W) — note that the biological assembly is a 2:2 TrkA-d5 / NGF dimer.
- Rotate: Left-click and drag
- Zoom: Scroll wheel
- Pan: Right-click (or Ctrl+Left-click) and drag
Design Mission
Design a protein that binds to the NGF-binding face of TrkA d5.
Target Specifications
| Feature | Detail |
|---|---|
| Target Name | TrkA d5 domain (extracellular, membrane-proximal Ig-like) |
| PDB ID | 1WWW (note: the Trk-NGF complex — not 1WWC, which is a monomer) |
| Target Chain | Chain X (TrkA-d5) |
| Binder to mimic | Chains V, W (NGF dimer) |
| Published interface hotspots | H291, V294–H298, C300, P302–S304, F327, L333–P335, H343–C345, R347, N349, Q350, T352–N355, M379–P382 |
| **Key “hot” residues” | F303, H343, R347, Q350, H353 dominate the direct contact surface; the ABED β-sheet face of d5 is the target |
These are every TrkA-d5 residue within 5 Å of NGF in 1WWW. The interface is large and relatively flat — a common feature of cytokine-receptor interfaces and a known difficult case for small-molecule drugs, but well-suited to de novo binder design.
Strategy Tips
- Download PDB
1WWW. - Clean the structure: Keep Chain X (TrkA-d5). Remove NGF (V, W) and any crystallographic partners.
- Define hotspots: Pass 4–6 residues from the hot set (e.g.,
X303,X343,X347,X350,X353) to RFdiffusion / BindCraft. - Beware of loop flexibility: The AB loop of d5 (residues 294–304) is somewhat flexible; designs that make contacts almost exclusively with this loop may not survive in solution. Balance contacts between the rigid β-sheet core and the loops.
Reference
- Wiesmann, C., Ultsch, M.H., Bass, S.H., de Vos, A.M. (1999). Crystal structure of nerve growth factor in complex with the ligand-binding domain of the TrkA receptor. Nature 401, 184–188. doi:10.1038/43705 — primary citation for 1WWW.